What do we call it when someone with high-risk practices becomes viraemic again after treatment? In this episode, experts discuss the challenges of managing Hepatitis C in people who inject drugs (PWID) and other high-risk groups. Topics include SVR confirmation rates, DAA prescribing practices, acute vs. chronic infection, and real-world reinfection data. Are traditional labels still meaningful or do we need new frameworks for 2025?
Faculty: Ahmed Elsharkawy (Moderator), Ashley Brown (Faculty), Tatyana Kushner (Faculty), Sabela Lens (Faculty)
This EASL Studio is supported by AbbVie. EASL has received no input from AbbVie with regards to the content of this programme.